Figure 5.
Cabozantinib has a strong anti-tumor effect on experimental HNSCC in mice
5 × 105 CAL33 or CAL33RR cells were injected subcutaneously into the flanks of nude mice. When the tumors reached 80 mm3, mice were treated five times a week for 4 weeks by gavage with placebo (dextrose water vehicle) or cabozantinib (40 mg/kg) or by intraperitoneal injection, three times per week with cisplatin (4 mg/kg). N = 8 mice per group.
(A and B) The tumor volume was measured twice weekly as described in the STAR methods.
(C) The tumor weight was measured at the end of the experiment.
(D) Necrosis was evaluated (HES staining).
(E) Detection of p-MET and p-AXL expression in the tumor. Representative images are shown.
(F) Ki67 immunohistochemistry (IHC) (proliferative cells). Representative images are shown.
(G) Detection of blood vessel CD31+ by IHC. Representative images are shown. Statistics were performed using ANOVA test: p values are indicated.